Kenvue Inc. (KVUE)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 14 | 15 | 15 | 15 | 15 | 15 | 15 | 16 |
| Operating profit | $bn | 3 | 3 | ||||||
| Net profit | $bn | -1 | 2 | 2 | 2 | 1 | 1 | 2 | 2 |
| EPS reported | $ | 0.76 | 0.87 | ||||||
| Operating cashflow per share | $ | 1.15 | 1.21 | ||||||
| Capex per share | $ | 0.25 | 0.11 | ||||||
| FCF per share | $ | 0.90 | 1.10 | ||||||
| Free cash flow | $bn | 2 | 2 | ||||||
| Net debt | $bn | 7 | 7 | ||||||
| Book value equity | $bn | 11 | 11 | ||||||
| Book value per share | $ | 5.60 | 5.49 | ||||||
| Number of shares | m | 1,924 | 1,923 | ||||||
| DPS (TTM paid) | $ | 0.83 | 1.04 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 22.62 | 20.46 | ||||||
| P/B LTM | x | 3.06 | 3.12 | ||||||
| P/S LTM | x | 2.18 | 2.14 | ||||||
| P/FCF LTM | x | 19.14 | 15.57 | ||||||
| EV/EBITDA LTM | x | 13.77 | 12.77 | ||||||
| EV/Sales LTM | x | 2.67 | 2.87 | ||||||
| Earnings Yield LTM | % | +4.42% | +4.89% | ||||||
| FCF Yield | % | +5.23% | +6.42% | ||||||
| Quality | |||||||||
| ROE | % | +13.66% | +15.58% | ||||||
| ROIC | % | +8.80% | +10.07% | ||||||
| Operating margin | % | +17.88% | +19.52% | ||||||
| Gross margin | % | +58.13% | +58.19% | ||||||
| FCF/Sales | % | +11.39% | +13.74% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +40.74% | +61.11% | ||||||
| Sales Growth YoY | % | -2.14% | -0.30% | ||||||
| Net Income Growth YoY | % | +42.72% | +60.97% | ||||||
| FCF Growth | % | +28.99% | +58.56% | ||||||
| Operating Profit Growth | % | +46.88% | +63.39% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +4.80% | +4.34% | ||||||
| Dividend Growth | % | +1.85% | +28.70% | ||||||
| Payout Ratio | % | +108.12% | +142.15% | ||||||
| FCF/Debt | x | 0.20 | 0.25 | ||||||
| Net Debt/EBITDA | x | 2.54 | 2.33 | ||||||
| EBIT/Net interest | x | 7.13 | 8.00 | ||||||
| Net debt/market cap | % | +25.87% | +23.00% | ||||||
| Net debt/Equity | x | 0.69 | 0.70 | ||||||
| Gross debt/equity | x | 0.79 | 0.80 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free